[8-K] Aprea Therapeutics, Inc. Common stock Reports Material Event

Rhea-AI Filing Summary

Aprea Therapeutics furnished a press release that announces its financial results for the three- and six-month periods ended June 30, 2025 and provided an operational update. The press release is attached as Exhibit 99.1 and the company also updated its corporate presentation, filed as Exhibit 99.2. The Form 8-K states that the information in Item 2.02 and Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

The 8-K itself does not include the underlying financial figures or metrics; it notifies investors that the detailed results and presentation materials are available in the referenced exhibits.

Insights

Securities Analyst

TL;DR: Routine earnings release and deck update; exhibits furnished but the 8-K contains no financial figures.

The filing indicates the company issued a press release disclosing results for the three- and six-month periods ended June 30, 2025 and updated its investor presentation. Because the company expressly states the press release is "furnished, not filed," the disclosure follows common practice for earnings releases and limits Section 18 liability. Investors should review Exhibits 99.1 and 99.2 for the substantive financial metrics and context; the 8-K serves as a notice rather than the primary source of numbers.

Corporate Governance Expert

TL;DR: Standard corporate disclosure; CEO signed the filing and exhibits are provided for investor review.

The Form 8-K documents routine communications: a press release with interim financial results and an updated corporate presentation. The report identifies Exhibits 99.1 and 99.2 and is signed by the President and CEO, Oren Gilad, Ph.D. There are no indications in the filing of leadership changes, material transactions, or governance concerns. The notation that the materials are furnished rather than filed is a procedural disclosure that is consistent with established practice.

0001781983false00017819832025-08-122025-08-12

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

August 12, 2025

Date of Report (Date of earliest event reported)

Aprea Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

​

​	​	​
Delaware	001-39069	84-2246769
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

​	​
3805 Old Easton Road Doylestown, PA (Address of principal executive offices)	18902 (Zip Code)

​

Registrant’s telephone number, including area code: (215) 948-4119

(Former name or former address, if changed since last report): Not applicable

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

​	​
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share	​	APRE	​	The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 2.02Results of Operations and Financial Condition.

On August 12, 2025, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2025, and provided an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

​

Item 8.01Other Events.

On August 12, 2025, the Company updated its corporate presentation slide deck. A copy of the corporate presentation slide deck is filed as Exhibit 99.2 hereto and incorporated herein by reference.

​

Item 9.01Financial Statements and Exhibits.

​

(d) Exhibits.

​	​	​
Exhibit Number		Description
99.1	​	Press release issued by Aprea Therapeutics, Inc. dated August 12, 2025.
99.2	​	Corporate Presentation (August 2025).
104	​	Cover Page Interactive Data File (embedded within the inline XBRL document).

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	​	​
​	Aprea Therapeutics, Inc.
​	​
Dated: August 12, 2025	By:	/s/ Oren Gilad
​	Name:	Oren Gilad, Ph.D.
​	Title:	President and Chief Executive Officer

​

​

​

​

FAQ

What did Aprea Therapeutics (APRE) disclose in this Form 8-K?

The company furnished a press release announcing financial results for the three- and six-month periods ended June 30, 2025 and updated its corporate presentation; Exhibits are 99.1 and 99.2.

Does the Form 8-K include the actual financial figures for Q2 2025?

No. The Form 8-K notifies investors that a press release with results was furnished as Exhibit 99.1; the filing text does not contain the underlying financial metrics.

Are the press release and presentation "filed" with the SEC?

The filing states the information, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

Which exhibits should investors consult for the detailed disclosure?

Consult Exhibit 99.1 for the press release with financial results and Exhibit 99.2 for the updated corporate presentation.

Who signed the Form 8-K for Aprea Therapeutics?

The Form 8-K is signed by Oren Gilad, Ph.D., President and Chief Executive Officer.

On which exchange is Aprea Therapeutics common stock listed and what is the ticker?

Aprea Therapeutics common stock is listed on The Nasdaq Stock Market LLC under the ticker APRE.